title: Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?
authors.forename: Dimitrios H
authors.initials: DH
authors.lastname: Roukos
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism; D035843:Biomedical Research / Q000379:methods; D055808:Drug Discovery / Q000379:methods / Q000458:organization & administration; D019008:Drug Resistance, Neoplasm; D018740:Genetic Heterogeneity; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D057285:Precision Medicine; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor